- Home
- DFIN vs BEAM Comparison
DFIN vs BEAM Comparison
Compare DFIN & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFIN
- BEAM
- Stock Information
- Founded
- DFIN 1983
- BEAM 2017
- Country
- DFIN United States
- BEAM United States
- Employees
- DFIN N/A
- BEAM N/A
- Industry
- DFIN Other Consumer Services
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DFIN Consumer Discretionary
- BEAM Health Care
- Exchange
- DFIN Nasdaq
- BEAM Nasdaq
- Market Cap
- DFIN 1.2B
- BEAM 1.6B
- IPO Year
- DFIN N/A
- BEAM 2020
- Fundamental
- Price
- DFIN $63.60
- BEAM $20.01
- Analyst Decision
- DFIN Strong Buy
- BEAM Strong Buy
- Analyst Count
- DFIN 3
- BEAM 11
- Target Price
- DFIN $68.67
- BEAM $48.90
- AVG Volume (30 Days)
- DFIN 257.9K
- BEAM 2.0M
- Earning Date
- DFIN 07-30-2025
- BEAM 08-05-2025
- Dividend Yield
- DFIN N/A
- BEAM N/A
- EPS Growth
- DFIN N/A
- BEAM N/A
- EPS
- DFIN 3.01
- BEAM N/A
- Revenue
- DFIN $779,600,000.00
- BEAM $63,578,000.00
- Revenue This Year
- DFIN $1.99
- BEAM N/A
- Revenue Next Year
- DFIN $4.64
- BEAM $8.82
- P/E Ratio
- DFIN $21.13
- BEAM N/A
- Revenue Growth
- DFIN N/A
- BEAM N/A
- 52 Week Low
- DFIN $37.80
- BEAM $13.53
- 52 Week High
- DFIN $71.01
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- DFIN 79.85
- BEAM 68.31
- Support Level
- DFIN $61.12
- BEAM $16.59
- Resistance Level
- DFIN $62.27
- BEAM $17.38
- Average True Range (ATR)
- DFIN 1.21
- BEAM 1.10
- MACD
- DFIN 0.09
- BEAM 0.35
- Stochastic Oscillator
- DFIN 97.66
- BEAM 89.70
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.